Cocrystal pharma's norovirus oral antiviral candidate demonstrates potent activity against the emerging gii.17 variants

Bothell, wash., april 24, 2025 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces that its investigative drug candidate cdi-988 was shown to bind to the highly conserved region of the gii.17 protease with excellent potency, similar to that shown across a range of gii.4 norovirus variants that had been the dominant worldwide strains until this year. the high resolution gii.17 protease crystal structures used in determining cdi-988's activity were obtained using the company's proprietary structure-based platform technology. cocrystal plans to initiate a human norovirus challenge study in 2025 in the u.s. to evaluate cdi-988 as a potential prevention and treatment of norovirus infection.
COCP Ratings Summary
COCP Quant Ranking